Company: NDRA
Filing Date: 2025-07-25
Form Type: S-1/A
Source: 0001654954-25-008477
Chunk: 59

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-07-25
Form: S-1/A
Chunk 59
---
 the date of the filing of such reports and documents.

You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address:

<div align='center'>ENDRA Life Sciences Inc.

3600 Green Court, Suite 350

Ann Arbor, Michigan 48105

Telephone: (734) 335-0468</div>

Exhibits to the filings will not be sent unless those exhibits have been specifically incorporated by reference in this prospectus.

| 38 |

<div align='center'>ENDRA Life Sciences Inc.

15,700,000 Shares of Common Stock

Pre-Funded Warrants to purchase up to 15,700,000 Shares of Common Stock

Underwriter Warrants to purchase up to 628,000 Shares of Common Stock

Up to 16,328,000 Shares of Common Stock underlying the Pre-Funded Warrants and Underwriter Warrants

_______________________

PROSPECTUS

_______________________

Sole Bookrunner

Lucid Capital Markets

___________, 2025</div>

| 39 |

<div align='center'>PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 13. Other Expenses of Issuance and Distribution.

The estimated expenses in connection with the sale of the securities being registered hereby, are as follows:

| SEC registration fee                 |     | $ |  10,020 |
| FINRA filing fee                     |     | $ |  10,318 |
| Accounting fees and expenses         |     | $ |  50,000 |
| Legal fees and expenses              |     | $ | 185,000 |
| Printing                             |     | $ |   5,000 |
| Expense reimbursement to Underwriter |     | $ | 100,000 |
| Miscellaneous                        |     | $ |  14,661 |
| Total                                |     | $ | 375,000 |

Item 14. Indemnification of Directors and Officers.

The following summary is qualified in its entirety by reference to the complete text of any statutes referred to below and the Fourth Amended and Restated Certificate of Incorporation of ENDRA Life Sciences Inc., a Delaware corporation.

Section 145 of the DGCL, or Section 145, provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative